Brussels Airport and United Cargo are aiming to capture growing pharmaceutical cargo volumes from Virginia through an enhanced airfreight corridor designed to strengthen temperature-controlled supply chains between the United States and Europe.
The initiative is expected to focus on high-value life sciences shipments, including vaccines, biologics, specialty medicines, and clinical materials that require strict handling standards and rapid transit. Virginia is home to a significant pharmaceutical and biotech presence, making it an attractive origin market for transatlantic cargo flows.
Brussels Airport has built a strong reputation as a specialised pharma logistics hub, supported by certified cold-chain infrastructure, dedicated handling facilities, and close links to European healthcare markets. Partnering with United Cargo could improve direct connectivity, transit reliability, and end-to-end visibility for shippers moving sensitive products.
Industry analysts note that pharmaceutical airfreight remains one of the most resilient and premium cargo segments, driven by growing healthcare demand, complex manufacturing networks, and strict quality requirements. Airports and airlines are increasingly competing to secure dedicated life sciences traffic through tailored services and compliance capabilities.
For United Cargo, the move supports broader efforts to expand high-yield cargo segments and deepen strategic partnerships across healthcare logistics. For Brussels Airport, attracting additional US-origin pharma traffic strengthens its position as one of Europe’s leading gateways for temperature-sensitive freight.
If successful, the corridor could create faster and more secure access for Virginia exporters to European markets while reinforcing specialised transatlantic supply chains in the pharmaceutical sector.
